Common Gene Therapy Viral Vectors Do Not Efficiently Penetrate Sputum from Cystic Fibrosis Patients

Abstract

Norwalk virus and human papilloma virus, two viruses that infect humans at mucosal surfaces, have been found capable of rapidly penetrating human mucus secretions. Viral vectors for gene therapy of Cystic Fibrosis (CF) must similarly penetrate purulent lung airway mucus (sputum) to deliver DNA to airway epithelial cells. However, surprisingly little is known about the rates at which gene delivery vehicles penetrate sputum, including viral vectors used in clinical trials for CF gene therapy. We find that sputum spontaneously expectorated by CF patients efficiently traps two viral vectors commonly used in CF gene therapy trials, adenovirus (d∼80 nm) and adeno-associated virus (AAV serotype 5; d∼20 nm), leading to average effective diffusivities that are ∼3,000-fold and 12,000-fold slower than their theoretical speeds in water, respectively. Both viral vectors are slowed by adhesion, as engineered muco-inert nanoparticles with diameters as large as 200 nm penetrate the same sputum samples at rates only ∼40-fold reduced compared to in pure water. A limited fraction of AAV exhibit sufficiently fast mobility to penetrate physiologically thick sputum layers, likely because of the lower viscous drag and smaller surface area for adhesion to sputum constituents. Nevertheless, poor penetration of CF sputum is likely a major contributor to the ineffectiveness of viral vector based gene therapy in the lungs of CF patients observed to date.

About the Authors:

Kaoru Hida

Affiliation: Department of Biomedical Engineering, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America

Samuel K. Lai

Affiliations Department of Chemical and Biomolecular Engineering, The Johns Hopkins University, Baltimore, Maryland, United States of America, Institute for NanoBioTechnology, The Johns Hopkins University, Baltimore, Maryland, United States of America

Jung Soo Suk

Affiliation: Department of Biomedical Engineering, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America

Sang Y. Won

Affiliation: Department of Chemical and Biomolecular Engineering, The Johns Hopkins University, Baltimore, Maryland, United States of America

Michael P. Boyle

Affiliations Institute for NanoBioTechnology, The Johns Hopkins University, Baltimore, Maryland, United States of America, Division of Pulmonary and Critical Care Medicine, Johns Hopkins Adult Cystic Fibrosis Program, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America

Justin Hanes

* E-mail: [email protected]

Affiliations Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America, Department of Biomedical Engineering, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America, Department of Chemical and Biomolecular Engineering, The Johns Hopkins University, Baltimore, Maryland, United States of America, Institute for NanoBioTechnology, The Johns Hopkins University, Baltimore, Maryland, United States of America, The Center for Nanomedicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America

Introduction

Nearly 20 years of clinical and laboratory research has thus far failed to realize successful gene therapy for cystic fibrosis (CF) [1], [2]. Viral gene vectors have dominated gene therapy efforts for CF, with adenovirus (AdV) and adeno-associated virus (AAV) representing two of the most widely tested systems to date [1], [2]. Although significant gene transfer has been observed for AdV and AAV vectors in cell lines and in a variety of animal models [3]–[5], neither vector has provided sufficient therapeutic end points in CF patients. Poor gene transfer has been attributed primarily to limited cellular uptake across the apical membrane of the lung airways, unproductive intracellular trafficking, vector toxicity, and immunological barriers [6].

We reasoned the CF sputum is a largely overlooked bottleneck that may limit gene therapy directed to the airways of CF patients. CF sputum possesses a bulk viscosity as high as 104–105 -fold greater than that of water at low shear [7], [8], and, thus, may physically exclude gene vectors from reaching epithelial cells. Although some viruses that infect mucosal surfaces (e.g. human papilloma virus and Norwalk virus) diffuse through human ovulatory cervical mucus as fast as through water [9], we recently found that other viruses (e.g. HIV and Herpes Simplex Virus) can be extensively trapped in non-ovulatory human cervicovaginal mucus collected from donors with healthy vaginal flora [10], [11]. Little is known about the ability of viral gene carriers commonly used in humans to penetrate CF sputum.

To investigate whether CF airway sputum serves as a transport barrier to viral vectors most commonly used in clinical trials, we performed high resolution multiple particle tracking (MPT) [12], [13] on both AdV and AAV serotype 5 (AAV5) in fresh, undiluted purulent sputum expectorated by CF patients. Although the average mesh spacing in purulent CF sputum (d ∼ 140±50 nm; range 60–300 nm) is substantially smaller than that in human cervicovaginal mucus (d ∼340±70 nm; range 50–1800 nm), the openings are sufficiently large that both AdV (d ∼80 nm) and AAV5 (d ∼20 nm) should readily penetrate CF sputum if they are not slowed by adhesive interactions with sputum constituents [11], [14].

Results and Discussion

Despite their native tropism for infecting airway cells, the diffusion of both AdV and AAV5 was strongly hindered in five of five independent human sputum samples. The highly constrained virus trajectories (Figure 1A & 1B) were similar to uncoated 200 nm polystyrene (PS) beads that are strongly immobilized in sputum (Figure 1C). We also tested 200 nm PS beads that were densely coated with low MW polyethylene glycol (PS-PEG), which we previously found to exhibit minimal adhesion to human mucus and CF sputum [11], [12], [14]. The PS-PEG particles exhibited traces spanning distances far larger than their diameters over the same duration in the same sputum samples (Figure 1D). We quantified the translational motions of particles and viruses by their time-scale dependent ensemble mean squared displacements (<MSD>). The ensemble-averaged <MSD> for AdV, AAV5 and muco-adhesive PS beads were all smaller than 10−2 µm2 across the time scales measured, whereas the <MSD> value for PS-PEG was at least 20-fold greater at a time scale of 1 s (Figure 2). AdV and AAV5 were slowed by over 3,000 and 12,000-fold in sputum compared to their theoretical speeds in water, respectively. In contrast, 200 nm PS-PEG particles were only slowed 40-fold in sputum as compared to in water. By fitting MSD vs. time scale (τ) to the equation MSD  = 4D0τα, where D0 is the time scale-independent diffusion coefficient, an average value for α can be obtained that provides insight into the extent of impediment to particle motion (α = 1 for purely Brownian, unobstructed diffusion; the lower the value of α, the more constrained the particle motion). The average α-value of AdV and AAV5 (∼0.37 for each) is comparable to that for PS beads (∼0.39) and indicative of substantial impediment to free diffusion. In contrast, the average α-value for PS-PEG particles was ∼0.70, reflecting motions markedly less hindered by sputum across the time scales examined. The diffusive nature and substantially faster speeds achieved with muco-inert synthetic particles (d∼200 nm; roughly 2.5 times larger than AdV and nearly 10 times larger than AAV5), and the markedly larger average pore size for CF sputum compared to the size of both viral vectors, suggest that the hindered diffusion of adenovirus and AAV5 cannot be attributed to steric hindrance from a dense sputum mesh or to the high bulk viscoelasticity of CF sputum. Instead, both viral vectors are likely trapped in sputum by adhesion, and the small and hindered motions for AdV and AAV5 likely reflects, in part, thermal motions of mucin fibers to which the viruses are bound.

[Figure omitted. See PDF.]

Figure 1. Sample 20 s trajectories.

Representative trajectories of (A) Adenovirus (Adv), (B) AAV5, (C) muco-adhesive PS control nanoparticles and (D) muco-inert control PS-PEG nanoparticles. All trajectories have MSD values within one standard deviation of the ensemble average.

https://doi.org/10.1371/journal.pone.0019919.g001

[Figure omitted. See PDF.]

Figure 2. Averaged ensemble mean squared displacements <MSD> of viral vectors and synthetic particles with respect to time scale.

Data represent n = 5 independent experiments with ∼100 particles tracked per experimental condition. Error bars represents standard error. *Statistically significant difference when compared with AAV5, AdV or PS (p<0.05).

https://doi.org/10.1371/journal.pone.0019919.g002

Despite the slow ensemble averaged virus penetration speeds, there may exist fast moving ‘outlier’ virions within the sample capable of rapidly penetrating the sputum layer and, thus, mediating gene transfer. To evaluate the effectiveness of the sputum barrier, it is thus essential to measure the transport rates of all individual viral particles and, in particular, the speeds of the most rapidly moving fractions. The use of MPT allowed collection of quantitative data on the transport of individual particles, data that would otherwise be unavailable with ensemble methods such as FRAP. We plotted the distribution of the logarithms of individual particle effective diffusivities (Deff) at a time scale of 1 s (Figure 3). Over 30% of the 200 nm PS-PEG particles exhibited Deff values greater than 0.1 µm/sec2, whereas only 0.4% and 0% of AdV and PS particles, respectively, exhibited such speeds (Figure 3). AAV5 had a higher fraction of faster moving particles, with 9% of virions displaying speeds greater than 0.1 µm/sec2. We used a Monte Carlo method that sorts the transport modes of particles based on their time-scale independent effective diffusion coefficients [12], [15]–[17], and found that over 98% of AdV and 90% of AAV were classified as either hindered or immobile, in good agreement with the distribution of effective diffusivities (Figure 4). It is not apparent whether the fast moving diffusive population of AAV5 represents a phenotypically unique subset of virions due to inherent vector packaging differences between individual virions, as the ratio of genomic particles to infective particles of AAV preparations can be as high as 200–10,000 [18]. It is unlikely that the differences in viral mobility can be attributed to the heterogeneity of the sputum microstructure, since the smallest pores present in CF sputum (range: 60–300 nm [14]) are substantially larger than the size of an AAV.

[Figure omitted. See PDF.]

Figure 3. Distribution of logarithms of individual particle effective diffusivities (Deff).

Distributions of Deff of AdV, AAV5, PS and PS-PEG particles represented as a percentage of particles in CF sputum at a time scale of 1 s.

https://doi.org/10.1371/journal.pone.0019919.g003

[Figure omitted. See PDF.]

Figure 4. Transport mode distributions of AdV, AAV5, PS and PS-PEG particles.

Particles were classified into either (i) immobile or hindered and (ii) diffusive [12], [15]–[17]. *Statistically significant difference when compared with AAV5, AdV or PS within the same transport mode classification (p<0.05).

https://doi.org/10.1371/journal.pone.0019919.g004

Based on our MSD measurements at short time scales, we used Fick's second law to estimate the fraction of AdV and AAV5 that may penetrate a sputum layer of a given thickness over time (Figure 5A). Although the thickness of CF sputum coating airways epithelial cells varies from patient to patient, by location within the respiratory tract, and likely depends on disease progression, most estimates are in the range of 10–55 µm [19]–[21]. Assuming the sputum layer to be 10 µm thick, only 0.4 and 2.7% of AdV and AAV5 are expected to penetrate after one hour, respectively (Figure 5B). In contrast, roughly 20% of the PS-PEG particles may penetrate the sputum layer over the same duration. If the sputum layer were 55 µm thick, we predict only 0.2% of AdV and 0.7% of AAV5 would be capable of penetrating within one hour, as compared to nearly 40% of PS-PEG particles.

[Figure omitted. See PDF.]

Figure 5. Theoretical model of particle penetration across a sputum layer.

(A) Schematic of the model, where particles are deposited in airway lumen on top of the CF sputum layer and must penetrate a 10 µm sputum layer to reach the epithelial cells. The pericilliary layer is much smaller in CF patients due to the collapsed cilia from the accumulated sputum [60]. (B) Estimated fraction of viral and synthetic particles that are capable of penetrating a 10 µm thick layer of CF sputum over time using Fick's second law. *Statistically significant difference when compared with AAV5, AdV or PS (p<0.05).

https://doi.org/10.1371/journal.pone.0019919.g005

While this analysis provides insight into the extent sputum may serve as a barrier to viral vectors, the fraction of vectors that can mediate gene transfer will likely be much smaller than this estimate. Upon reaching the epithelial cells, the glycocalyx and the paucity of receptors on the apical membrane further limit cell entry [6], [22]. The efficiency of AAV entry into unpolarized cells was 13% [23] and likely even lower for polarized epithelium [24]. After endocytosis, numerous potentially rate-limiting intracellular events must also be overcome for successful transduction [25], [26]. Nevertheless, the limited gene carrier penetration observed here in purulent CF sputum helps to explain the very poor gene transfer observed with AAV in the human airways as compared to human nares, since CF sputum in the lung likely constitutes a far more tenacious barrier than sputum in human nares or mucus in the lungs of other animals [27], [28]. Previously, aerosol doses as high as 2.5×1010 infectious adenovirus (AdV) were administered to CF patients, but ≤2.4% of airway cells were shown to contain nuclear localized vector DNA, as estimated by fluorescence in situ hybridization experiments [29]. A major Phase II clinical trial utilizing AAV was also recently dropped due to inadequate efficacy, even though efficient gene transfer was evident in both rabbits and monkeys [30], as well as in the maxillary sinuses of humans [31].

The extracellular fluids in the lung have long been considered an integral part of a complex barrier that minimizes infections of the airway epithelia. For example, the airway surface liquid has both antimicrobial and antiviral properties, with high concentrations of lysozyme [32] and antibodies [33]. Antibodies were found to limit adenoviral infection of airway epithelium in both animal models and humans [33]–[35]. In CF patients, proteins associated with chronic inflammation, such as high concentrations of uninhibited neutrophil elastase [36], may further decrease vector efficiency. Recent studies have shown that bronchoalveolar lavage [29] fluid from CF patients reduces both AdV and AAV2-mediated gene transfer [37]–[39]. Although it has been reported that AAV5 transduction is maintained in the presence of BAL fluids from CF patients [40], 20% of the population harbor neutralizing antibodies against AAV5 [41]. The results presented here indicate that CF sputum can also act as a critical diffusional barrier, trapping viral vectors via adhesion and, thereby, limiting penetration. The reduced penetration speeds of viruses in sputum are also likely to increase the probability of viral inactivation by native protective mechanisms.

Although the specific nature of the adhesive interactions between viral vectors and sputum constituents remain unclear, it is likely a complex interplay of adhesion based on hydrophobic, ionic, hydrogen-bonding and/or van der Waals interactions. Mucins, the primary building block of CF sputum, are highly flexible molecules that are densely glycosylated, and therefore carry a negative charge due to the presence of carboxyl or sulfate groups. In addition, they also contain periodic hydrophobic “naked” globular regions interspersed along the mucin fibers, stabilized by multiple internal disulfide bonds [42]. Thus, mucins may form hydrophobic, electrostatic and/or hydrogen bonding adhesive interactions with foreign particles [43]. Elevated levels of bacterial and endogenous DNA, as well as actin filaments from degraded neutrophils in CF sputum, further contributes to its dense mesh structure and increased adhesivity [43]–[45]. The high density of adhesive domains, coupled with the highly flexible nature of mucins and other macromolecules, allows formation of multiple adhesive interactions with surfaces of foreign particles [43]. Even if each adhesive interaction is low affinity and can be readily disrupted by thermal energy, a large number of low-affinity adhesive interactions with the sputum mesh can effectively immobilize particles with permanent high viscidity [46]. Alternatively, it is possible that some viruses may bind directly to specific domains along mucins. For example, AAV4 binds to O-linked sialic acids highly expressed on mucins in CF sputum, and presence of MUC1 inhibited gene transfer with AAV4 [47]. While AAV5 also binds to 2,3-linked sialic acids, AAV5 interacts with sialic acids on N-linked carbohydrates which are rarely expressed on mucins, and MUC1 did not block gene transfer with AAV5 [47].

Although a number of scientists initially speculated that only 6–10% of airway epithelial cells need to have CFTR corrected to restore Cl− transport in an in vitro cell culture model [48], it is now thought that a larger number of cells must be transduced for the normalization of both Cl− secretion and Na+ absorption [49]. While the number of cells that need to be genetically corrected for clinical benefit remains unresolved, improved gene carrier penetration across the sputum layer is likely a critical step towards more reliable gene transfer in the CF lung airways. Our results suggest that engineering muco-inert surfaces on virus-sized particles can greatly improve vector penetration through purulent CF sputum. One possible approach may be to engineer viral vectors lacking specific surface epitopes that cause them to adhere to sputum constituents. For example, Muzyczka and colleagues have engineered AAV2 mutants without the normal heparin sulfate binding of the virus and discovered that the mutant virus produced a larger area of transduction upon injection in the striata of rat brains (unpublished observations; personal communication). This was presumably due to the increased diffusion of mutant AAV2 in the brain. In the scenario where specific epitopes responsible for mucoadhesion is not known, an alternative approach may be to employ directed evolution techniques to evolve non-mucoadhesive viruses. This approach is exemplified by previous work that evolved AAV vectors more efficient at CFTR delivery to human ciliated airway epithelium, or AAV vectors that evade neutralizing antibodies [50], [51].

Alternatively, vector penetration across sputum may be enhanced with adjuvant therapies targeted at reducing the barrier properties of CF sputum, such as bronchoalveoloar lavage (BAL) to reduce sputum, or clinically prescribed mucolytics that degrade specific constituents of the sputum mesh [43]. Two commonly prescribed mucolytic agents, N-acetyl-cysteine (NAC; Mucomyst ®) and recombinant human DNAse (rhDNAse; Pulmozyme ®), have been shown to reduce the bulk rheological properties of CF sputum [52]–[54]. Dawson et al previously found that rhDNase treatment failed to improve the diffusion of polystyrene nanoparticles in CF sputum [7], whereas Suk et al showed that NAC markedly enhanced the diffusion of coated, muco-inert nanoparticles in CF sputum, but not the diffusion of uncoated particles that were muco-adhesive [55]. It remains to be determined whether these mucolytic treatments will enhance or hinder viral vector transport.

We have demonstrated that human CF sputum is likely a critical barrier to overcome for successful CF gene therapy. Much of the current effort on improving AAV vectors for CF gene therapy has focused on identifying and characterizing novel variants of AAV with improved lung tropism. For example, AAV serotype 1 and 6 has been shown to transduce airway epithelia in mice or polarized human cell cultures significantly more efficiently than the most widely tested serotype, AAV2 [56], [57]. Further efforts have led to the development of AAV6.2, with a single point mutation and a 2-fold improvement in the transduction of airway epithelium compared to parental AAV6 vectors in both in vivo mouse studies and in vitro human ciliated airway epithelium [58]. However, improved vector penetration across sputum remains a critical step to reduce the viral dosage necessary for efficient transduction in the CF lung. Our work further suggests that high transgene expression in cell culture models or in animal models may not be sufficient justification to initiate clinical trials in CF patients without evidence that the same systems are capable of penetrating sputum.

Materials and Methods

Ethics Statement

Sputum samples were collected at the Johns Hopkins Adult Cystic Fibrosis Program conforming to ethical standards of the Johns Hopkins Medicine Institutional Review Board. Written informed consent was obtained from all participants.

Collection of Cystic Fibrosis Sputum

Same day samples were placed on ice upon collection, pooled together to minimize patient-to-patient variability and used within 24 hrs. The barrier properties of collected sputum were confirmed by tracking fluorescent polystyrene (PS) beads that undergo polyvalent adhesive interactions with sputum [14].

Preparation of Fluorescent Viruses and Particles

Green fluorescent protein–labeled AdV was constructed and generously provided by Dr. Curiel (University of Alabama). AlexaFluor 488 labeled AAV5 was provided by Dr. Chiorini (NIH). Fluorescent uncoated polystyrene nanoparticles with carboxyl-modified surfaces (Molecular Probes, Eugene, OR) were used as provided. PEG-coated nanoparticles were prepared by covalently modified surface carboxyl groups with polyethylene glycol (PEG) as described previously [12], [14]. Size and ζ-potential (surface charge) of nanoparticles were determined by Zetasizer Nano ZS90 (Malvern Instruments, Southborough, MA) to confirm dense PEG conjugation [12], [59].

Multiple Particle Tracking (MPT)

Fluorescently labeled virions were added to ∼30 µl of CF sputum at minimal dilution (3% v/v), placed in a custom made glass chamber and incubated for 30 minutes prior to microscopy. Movies were captured on an EMCCD camera (Cascade II: 512, Photometrics, Tucson AZ) mounted on an inverted epifluorescence microscope (3-I Marianas, Zeiss, Thornwood, NY) equipped with a 100X oil-immersion objective (numerical aperture 1.3). Movies were recorded at a temporal resolution of 66.7 ms for 20 s using Slidebook 4.2 Advanced Imaging software (Universal Imaging Corp. Downington, PA). Movies were analyzed with Metamorph software (Universal Imaging Corp. Downington, PA) to extract x, y positional data over time. Time-averaged mean square displacement (MSD) and effective diffusivity.

(Deff) for each particle were calculated as a function of time scale (s) [12], [14]. CF sputum was assumed to be locally isotropic but not necessarily homogeneous; thus, 2D diffusivity is equal to 3D diffusivity (see review [13] for more details). Five independent experiments in sputum from different days, with n∼100 virions per experiment, were performed. Average transport rates were calculated by geometric ensemble-averaging of individual transport rates. Particle transport mechanism (immobile, hindered, and diffusive) was classified as discussed previously [12], [16]. Briefly, the mechanism of particle transport over short and long time scales was classified based on the concept of relative change (RC) of Deff. RC values of particles at short and long time scales were calculated by dividing the Deff of a particle at a probed time scale by the Deff at an earlier reference time scale. By calculating RC values for two time regimes (i.e., short and long time scales), one can obtain the transport mode that describes the particle transport properties over different length and temporal scales. Particles undergoing hindered diffusion are expected to possess RC values below that for typical diffusive particles. Due to the random nature of diffusion, however, the RC values of a population of purely diffusive particles will have a certain spread around the value 1. Therefore, a Monte Carlo simulation of 10,000 random walks was used to predict this distribution of RC values (please see [16] for more details). The tracking resolution was 10 nm, as determined by tracking particles immobilized with a strong adhesive [12], [13].

Particle Penetration Model

Speeds of individual particles, obtained from particle tracking data, were projected to 2 hours using the measured <MSD> versus τ relationship. Concentration profiles over time were obtained by numerically integrating Fick's second law, du/dt  =  Deff d2u/dx2 with the initial condition of particles present at the apical side (u(x,0)  = 1 when x  = 0, u(x,0)  = 0 otherwise) and boundary conditions of constant particle concentration at the apical side (u(0,t)  = 1) and no flux out across the epithelium (du/dx|x = 10  = 0).

Statistical Analysis

Statistical significance between two groups was determined with the one-sided student's t-test under the assumption of unequal variance. P-values less than 0.05 were considered significant.

Acknowledgments

We thank Benjamin C. Tang for assistance with the diffusion model.

Author Contributions

Conceived and designed the experiments: KH SKL JH. Performed the experiments: KH SKL JSS SYW. Analyzed the data: KH SKL JSS SYW. Contributed reagents/materials/analysis tools: MPB. Wrote the paper: KH SKL JSS SYW MPB JH.

Citation: Hida K, Lai SK, Suk JS, Won SY, Boyle MP, Hanes J (2011) Common Gene Therapy Viral Vectors Do Not Efficiently Penetrate Sputum from Cystic Fibrosis Patients. PLoS ONE6(5): e19919. https://doi.org/10.1371/journal.pone.0019919

References

1. Griesenbach U, Geddes DM, Alton EW (2006) Gene therapy progress and prospects: cystic fibrosis. Gene Ther 13: 1061–1067.U. GriesenbachDM GeddesEW Alton2006Gene therapy progress and prospects: cystic fibrosis.Gene Ther1310611067

2. Griesenbach U, Geddes DM, Alton EW (2004) Gene therapy for cystic fibrosis: an example for lung gene therapy. Gene Ther 11: Suppl 1S43–50.U. GriesenbachDM GeddesEW Alton2004Gene therapy for cystic fibrosis: an example for lung gene therapy.Gene Ther11Suppl 1S4350

3. Conrad CK, Allen SS, Afione SA, Reynolds TC, Beck SE, et al. (1996) Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung. Gene Ther 3: 658–668.CK ConradSS AllenSA AfioneTC ReynoldsSE Beck1996Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung.Gene Ther3658668

4. Rosenfeld MA, Yoshimura K, Trapnell BC, Yoneyama K, Rosenthal ER, et al. (1992) In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 68: 143–155.MA RosenfeldK. YoshimuraBC TrapnellK. YoneyamaER Rosenthal1992In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium.Cell68143155

5. Simon RH, Engelhardt JF, Yang Y, Zepeda M, Weber-Pendleton S, et al. (1993) Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates: toxicity study. Hum Gene Ther 4: 771–780.RH SimonJF EngelhardtY. YangM. ZepedaS. Weber-Pendleton1993Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates: toxicity study.Hum Gene Ther4771780

6. Ferrari S, Geddes DM, Alton EW (2002) Barriers to and new approaches for gene therapy and gene delivery in cystic fibrosis. Adv Drug Deliv Rev 54: 1373–1393.S. FerrariDM GeddesEW Alton2002Barriers to and new approaches for gene therapy and gene delivery in cystic fibrosis.Adv Drug Deliv Rev5413731393

7. Dawson M, Wirtz D, Hanes J (2003) Enhanced viscoelasticity of human cystic fibrotic sputum correlates with increasing microheterogeneity in particle transport. J Biol Chem 278: 50393–50401.M. DawsonD. WirtzJ. Hanes2003Enhanced viscoelasticity of human cystic fibrotic sputum correlates with increasing microheterogeneity in particle transport.J Biol Chem2785039350401

8. Lai SK, Wang YY, Wirtz D, Hanes J (2009) Micro- and macrorheology of mucus. Adv Drug Deliv Rev 61: 86–100.SK LaiYY WangD. WirtzJ. Hanes2009Micro- and macrorheology of mucus.Adv Drug Deliv Rev6186100

9. Olmsted SS, Padgett JL, Yudin AI, Whaley KJ, Moench TR, et al. (2001) Diffusion of macromolecules and virus-like particles in human cervical mucus. Biophys J 81: 1930–1937.SS OlmstedJL PadgettAI YudinKJ WhaleyTR Moench2001Diffusion of macromolecules and virus-like particles in human cervical mucus.Biophys J8119301937

10. Lai SK, Hida K, Shukair S, Wang YY, Figueiredo A, et al. (2009) Human immunodeficiency virus type 1 is trapped by acidic but not by neutralized human cervicovaginal mucus. J Virol 83: 11196–11200.SK LaiK. HidaS. ShukairYY WangA. Figueiredo2009Human immunodeficiency virus type 1 is trapped by acidic but not by neutralized human cervicovaginal mucus.J Virol831119611200

11. Lai SK, Wang YY, Hida K, Cone R, Hanes J (2010) Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than viruses. Proc Natl Acad Sci U S A 107: 598–603.SK LaiYY WangK. HidaR. ConeJ. Hanes2010Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than viruses.Proc Natl Acad Sci U S A107598603

12. Lai SK, O'Hanlon DE, Harrold S, Man ST, Wang YY, et al. (2007) Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc Natl Acad Sci U S A 104: 1482–1487.SK LaiDE O'HanlonS. HarroldST ManYY Wang2007Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus.Proc Natl Acad Sci U S A10414821487

13. Suh J, Dawson M, Hanes J (2005) Real-time multiple-particle tracking: applications to drug and gene delivery. Adv Drug Deliv Rev 57: 63–78.J. SuhM. DawsonJ. Hanes2005Real-time multiple-particle tracking: applications to drug and gene delivery.Adv Drug Deliv Rev576378

14. Suk JS, Lai SK, Wang YY, Ensign LM, Zeitlin PL, et al. (2009) The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles. Biomaterials 30: 2591–2597.JS SukSK LaiYY WangLM EnsignPL Zeitlin2009The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles.Biomaterials3025912597

15. Lai SK, Hida K, Chen C, Hanes J (2008) Characterization of the intracellular dynamics of a non-degradative pathway accessed by polymer nanoparticles. J Control Release 125: 107–111.SK LaiK. HidaC. ChenJ. Hanes2008Characterization of the intracellular dynamics of a non-degradative pathway accessed by polymer nanoparticles.J Control Release125107111

16. Suh J, Choy KL, Lai SK, Suk JS, Tang BC, et al. (2007) PEGylation of nanoparticles improves their cytoplasmic transport. Int J Nanomedicine 2: 735–741.J. SuhKL ChoySK LaiJS SukBC Tang2007PEGylation of nanoparticles improves their cytoplasmic transport.Int J Nanomedicine2735741

17. Suk JS, Suh J, Lai SK, Hanes J (2007) Quantifying the intracellular transport of viral and nonviral gene vectors in primary neurons. Exp Biol Med (Maywood) 232: 461–469.JS SukJ. SuhSK LaiJ. Hanes2007Quantifying the intracellular transport of viral and nonviral gene vectors in primary neurons.Exp Biol Med (Maywood)232461469

18. Zolotukhin S, Byrne BJ, Mason E, Zolotukhin I, Potter M, et al. (1999) Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 6: 973–985.S. ZolotukhinBJ ByrneE. MasonI. ZolotukhinM. Potter1999Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield.Gene Ther6973985

19. Clunes MT, Boucher RC (2007) Cystic Fibrosis: The Mechanisms of Pathogenesis of an Inherited Lung Disorder. Drug Discov Today Dis Mech 4: 63–72.MT ClunesRC Boucher2007Cystic Fibrosis: The Mechanisms of Pathogenesis of an Inherited Lung Disorder.Drug Discov Today Dis Mech46372

20. Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, et al. (2006) Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 354: 241–250.SH DonaldsonWD BennettKL ZemanMR KnowlesR. Tarran2006Mucus clearance and lung function in cystic fibrosis with hypertonic saline.N Engl J Med354241250

21. Matsui H, Grubb BR, Tarran R, Randell SH, Gatzy JT, et al. (1998) Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 95: 1005–1015.H. MatsuiBR GrubbR. TarranSH RandellJT Gatzy1998Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease.Cell9510051015

22. Boucher RC (1999) Status of gene therapy for cystic fibrosis lung disease. J Clin Invest 103: 441–445.RC Boucher1999Status of gene therapy for cystic fibrosis lung disease.J Clin Invest103441445

23. Seisenberger G, Ried MU, Endress T, Buning H, Hallek M, et al. (2001) Real-time single-molecule imaging of the infection pathway of an adeno-associated virus. Science 294: 1929–1932.G. SeisenbergerMU RiedT. EndressH. BuningM. Hallek2001Real-time single-molecule imaging of the infection pathway of an adeno-associated virus.Science29419291932

24. Duan D, Yue Y, Yan Z, McCray PB Jr, Engelhardt JF (1998) Polarity influences the efficiency of recombinant adenoassociated virus infection in differentiated airway epithelia. Hum Gene Ther 9: 2761–2776.D. DuanY. YueZ. YanPB McCray JrJF Engelhardt1998Polarity influences the efficiency of recombinant adenoassociated virus infection in differentiated airway epithelia.Hum Gene Ther927612776

25. Ding W, Zhang L, Yan Z, Engelhardt JF (2005) Intracellular trafficking of adeno-associated viral vectors. Gene Ther 12: 873–880.W. DingL. ZhangZ. YanJF Engelhardt2005Intracellular trafficking of adeno-associated viral vectors.Gene Ther12873880

26. Hansen J, Qing K, Kwon HJ, Mah C, Srivastava A (2000) Impaired intracellular trafficking of adeno-associated virus type 2 vectors limits efficient transduction of murine fibroblasts. J Virol 74: 992–996.J. HansenK. QingHJ KwonC. MahA. Srivastava2000Impaired intracellular trafficking of adeno-associated virus type 2 vectors limits efficient transduction of murine fibroblasts.J Virol74992996

27. Grubb BR, Boucher RC (1999) Pathophysiology of gene-targeted mouse models for cystic fibrosis. Physiol Rev 79: S193–214.BR GrubbRC Boucher1999Pathophysiology of gene-targeted mouse models for cystic fibrosis.Physiol Rev79S193214

28. Snouwaert JN, Brigman KK, Latour AM, Malouf NN, Boucher RC, et al. (1992) An animal model for cystic fibrosis made by gene targeting. Science 257: 1083–1088.JN SnouwaertKK BrigmanAM LatourNN MaloufRC Boucher1992An animal model for cystic fibrosis made by gene targeting.Science25710831088

29. Joseph PM, O'Sullivan BP, Lapey A, Dorkin H, Oren J, et al. (2001) Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. I. Methods, safety, and clinical implications. Hum Gene Ther 12: 1369–1382.PM JosephBP O'SullivanA. LapeyH. DorkinJ. Oren2001Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. I. Methods, safety, and clinical implications.Hum Gene Ther1213691382

30. Moss RB, Milla C, Colombo J, Accurso F, Zeitlin PL, et al. (2007) Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: A Randomized placebo-controlled phase 2B trial. Human Gene Therapy 18: 726–732.RB MossC. MillaJ. ColomboF. AccursoPL Zeitlin2007Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: A Randomized placebo-controlled phase 2B trial.Human Gene Therapy18726732

31. Wagner JA, Reynolds T, Moran ML, Moss RB, Wine JJ, et al. (1998) Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus. Lancet 351: 1702–1703.JA WagnerT. ReynoldsML MoranRB MossJJ Wine1998Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus.Lancet35117021703

32. Travis SM, Conway BA, Zabner J, Smith JJ, Anderson NN, et al. (1999) Activity of abundant antimicrobials of the human airway. Am J Respir Cell Mol Biol 20: 872–879.SM TravisBA ConwayJ. ZabnerJJ SmithNN Anderson1999Activity of abundant antimicrobials of the human airway.Am J Respir Cell Mol Biol20872879

33. Gahery-Segard H, Molinier-Frenkel V, Le Boulaire C, Saulnier P, Opolon P, et al. (1997) Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products. J Clin Invest 100: 2218–2226.H. Gahery-SegardV. Molinier-FrenkelC. Le BoulaireP. SaulnierP. Opolon1997Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products.J Clin Invest10022182226

34. Kaplan JM, St George JA, Pennington SE, Keyes LD, Johnson RP, et al. (1996) Humoral and cellular immune responses of nonhuman primates to long-term repeated lung exposure to Ad2/CFTR-2. Gene Ther 3: 117–127.JM KaplanJA St GeorgeSE PenningtonLD KeyesRP Johnson1996Humoral and cellular immune responses of nonhuman primates to long-term repeated lung exposure to Ad2/CFTR-2.Gene Ther3117127

35. Yang Y, Trinchieri G, Wilson JM (1995) Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nat Med 1: 890–893.Y. YangG. TrinchieriJM Wilson1995Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung.Nat Med1890893

36. Konstan MW, Hilliard KA, Norvell TM, Berger M (1994) Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med 150: 448–454.MW KonstanKA HilliardTM NorvellM. Berger1994Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation.Am J Respir Crit Care Med150448454

37. Perricone MA, Rees DD, Sacks CR, Smith KA, Kaplan JM, et al. (2000) Inhibitory effect of cystic fibrosis sputum on adenovirus-mediated gene transfer in cultured epithelial cells. Hum Gene Ther 11: 1997–2008.MA PerriconeDD ReesCR SacksKA SmithJM Kaplan2000Inhibitory effect of cystic fibrosis sputum on adenovirus-mediated gene transfer in cultured epithelial cells.Hum Gene Ther1119972008

38. Stern M, Caplen NJ, Browning JE, Griesenbach U, Sorgi F, et al. (1998) The effect of mucolytic agents on gene transfer across a CF sputum barrier in vitro. Gene Ther 5: 91–98.M. SternNJ CaplenJE BrowningU. GriesenbachF. Sorgi1998The effect of mucolytic agents on gene transfer across a CF sputum barrier in vitro.Gene Ther59198

39. Virella-Lowell I, Poirier A, Chesnut KA, Brantly M, Flotte TR (2000) Inhibition of recombinant adeno-associated virus (rAAV) transduction by bronchial secretions from cystic fibrosis patients. Gene Ther 7: 1783–1789.I. Virella-LowellA. PoirierKA ChesnutM. BrantlyTR Flotte2000Inhibition of recombinant adeno-associated virus (rAAV) transduction by bronchial secretions from cystic fibrosis patients.Gene Ther717831789

40. Rooney CP, Denning GM, Davis BP, Flaherty DM, Chiorini JA, et al. (2002) Bronchoalveolar fluid is not a major hindrance to virus-mediated gene therapy in cystic fibrosis. J Virol 76: 10437–10443.CP RooneyGM DenningBP DavisDM FlahertyJA Chiorini2002Bronchoalveolar fluid is not a major hindrance to virus-mediated gene therapy in cystic fibrosis.J Virol761043710443

41. Halbert CL, Miller AD, McNamara S, Emerson J, Gibson RL, et al. (2006) Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors. Hum Gene Ther 17: 440–447.CL HalbertAD MillerS. McNamaraJ. EmersonRL Gibson2006Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors.Hum Gene Ther17440447

42. Sheehan JK, Oates K, Carlstedt I (1986) Electron microscopy of cervical, gastric and bronchial mucus glycoproteins. Biochem J 239: 147–153.JK SheehanK. OatesI. Carlstedt1986Electron microscopy of cervical, gastric and bronchial mucus glycoproteins.Biochem J239147153

43. Lai SK, Wang YY, Hanes J (2009) Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev 61: 158–171.SK LaiYY WangJ. Hanes2009Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues.Adv Drug Deliv Rev61158171

44. Sanders N, Rudolph C, Braeckmans K, De Smedt SC, Demeester J (2009) Extracellular barriers in respiratory gene therapy. Adv Drug Deliv Rev 61: 115–127.N. SandersC. RudolphK. BraeckmansSC De SmedtJ. Demeester2009Extracellular barriers in respiratory gene therapy.Adv Drug Deliv Rev61115127

45. Voynow JA, Rubin BK (2009) Mucins, mucus, and sputum. Chest 135: 505–512.JA VoynowBK Rubin2009Mucins, mucus, and sputum.Chest135505512

46. Cone R (1999) Mucus. In: Michael E, Lamm WS, McGhee JerryR, Mayer Lloyd, Mestecky Jiri, Bienenstock John, editors. Mucosal Immunlogy. 3 ed. San Diego: Academic Press. pp. 43–64.R. Cone1999Mucus.E. MichaelWS LammJerryR McGheeLloyd MayerJiri MesteckyJohn BienenstockMucosal Immunlogy3 ed. San DiegoAcademic Press4364

47. Walters RW, Pilewski JM, Chiorini JA, Zabner J (2002) Secreted and transmembrane mucins inhibit gene transfer with AAV4 more efficiently than AAV5. J Biol Chem 277: 23709–23713.RW WaltersJM PilewskiJA ChioriniJ. Zabner2002Secreted and transmembrane mucins inhibit gene transfer with AAV4 more efficiently than AAV5.J Biol Chem2772370923713

48. Johnson LG, Olsen JC, Sarkadi B, Moore KL, Swanstrom R, et al. (1992) Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nat Genet 2: 21–25.LG JohnsonJC OlsenB. SarkadiKL MooreR. Swanstrom1992Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis.Nat Genet22125

49. Mueller C, Flotte TR (2008) Gene Therapy for Cystic Fibrosis. Clin Rev Allergy Immunol 35: 164–178.C. MuellerTR Flotte2008Gene Therapy for Cystic Fibrosis.Clin Rev Allergy Immunol35164178

50. Li W, Zhang L, Johnson JS, Zhijian W, Grieger JC, et al. (2009) Generation of novel AAV variants by directed evolution for improved CFTR delivery to human ciliated airway epithelium. Mol Ther 17: 2067–2077.W. LiL. ZhangJS JohnsonW. ZhijianJC Grieger2009Generation of novel AAV variants by directed evolution for improved CFTR delivery to human ciliated airway epithelium.Mol Ther1720672077

51. Maheshri N, Koerber JT, Kaspar BK, Schaffer DV (2006) Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat Biotechnol 24: 198–204.N. MaheshriJT KoerberBK KasparDV Schaffer2006Directed evolution of adeno-associated virus yields enhanced gene delivery vectors.Nat Biotechnol24198204

52. Zahm JM, Debordeaux C, Maurer C, Hubert D, Dusser D, et al. (2001) Improved activity of an actin-resistant DNase I variant on the cystic fibrosis airway secretions. Am J Respir Crit Care Med 163: 1153–1157.JM ZahmC. DebordeauxC. MaurerD. HubertD. Dusser2001Improved activity of an actin-resistant DNase I variant on the cystic fibrosis airway secretions.Am J Respir Crit Care Med16311531157

53. Vasconcellos CA, Allen PG, Wohl ME, Drazen JM, Janmey PA, et al. (1994) Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin. Science 263: 969–971.CA VasconcellosPG AllenME WohlJM DrazenPA Janmey1994Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin.Science263969971

54. Dasgupta B, King M (1996) Reduction in viscoelasticity in cystic fibrosis sputum in vitro using combined treatment with nacystelyn and rhDNase. Pediatr Pulmonol 22: 161–166.B. DasguptaM. King1996Reduction in viscoelasticity in cystic fibrosis sputum in vitro using combined treatment with nacystelyn and rhDNase.Pediatr Pulmonol22161166

55. Suk JS, Lai SK, Boylan NJ, Dawson MR, Boyle MP, et al. (2011) Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine. Nanomedicine (Lond) 6: 365–375.JS SukSK LaiNJ BoylanMR DawsonMP Boyle2011Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine.Nanomedicine (Lond)6365375

56. Halbert CL, Allen JM, Miller AD (2001) Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors. J Virol 75: 6615–6624.CL HalbertJM AllenAD Miller2001Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors.J Virol7566156624

57. Yan Z, Lei-Butters DC, Liu X, Zhang Y, Zhang L, et al. (2006) Unique biologic properties of recombinant AAV1 transduction in polarized human airway epithelia. J Biol Chem 281: 29684–29692.Z. YanDC Lei-ButtersX. LiuY. ZhangL. Zhang2006Unique biologic properties of recombinant AAV1 transduction in polarized human airway epithelia.J Biol Chem2812968429692

58. Limberis MP, Vandenberghe LH, Zhang L, Pickles RJ, Wilson JM (2009) Transduction efficiencies of novel AAV vectors in mouse airway epithelium in vivo and human ciliated airway epithelium in vitro. Mol Ther 17: 294–301.MP LimberisLH VandenbergheL. ZhangRJ PicklesJM Wilson2009Transduction efficiencies of novel AAV vectors in mouse airway epithelium in vivo and human ciliated airway epithelium in vitro.Mol Ther17294301

59. Wang YY, Lai SK, Suk JS, Pace A, Cone R, et al. (2008) Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that “slip” through the human mucus barrier. Angew Chem Int Ed Engl 47: 9726–9729.YY WangSK LaiJS SukA. PaceR. Cone2008Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that “slip” through the human mucus barrier.Angew Chem Int Ed Engl4797269729

60. Boucher RC (2007) Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. Annu Rev Med 58: 157–170.RC Boucher2007Airway surface dehydration in cystic fibrosis: pathogenesis and therapy.Annu Rev Med58157170